<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03981198</url>
  </required_header>
  <id_info>
    <org_study_id>Soliton 2018-001</org_study_id>
    <nct_id>NCT03981198</nct_id>
  </id_info>
  <brief_title>Proof of Concept (POC) Study of the Soliton Rapid Acoustic (RAP) for the Treatment of Cellulite</brief_title>
  <official_title>Proof of Concept (POC) Study of the Soliton Rapid Acoustic (RAP) Nov Heavy Device for the Treatment of Cellulite</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soliton</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soliton</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Feasibility study is to evaluate the safety, tolerability and efficacy of Soliton's Rapid
      Acoustic Pulse (RAP) device for the treatment of cellulite
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the safety and tolerability of Soliton's RAP Nov Heavy for the treatment of
      cellulite. To assess the efficacy of Soliton's RAP Nov Heavy device for the temporary
      improvement in appearance of cellulite in terms of mean change in cellulite severity score
      (CSS).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Actual">August 5, 2019</completion_date>
  <primary_completion_date type="Actual">August 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of SAEs</measure>
    <time_frame>18 weeks</time_frame>
    <description>The primary safety endpoint will be met if all treated Participants are free from serious adverse events (SAEs) attributable to the RAP device immediately post treatment and at the 3-month follow-up visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Tolerability</measure>
    <time_frame>18 Weeks</time_frame>
    <description>The primary endpoint will be met if a mean tolerability measure using pain scores averaged across all treated Participants is &lt; 8.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Celluite improvement</measure>
    <time_frame>18 weeks</time_frame>
    <description>A ≥15% mean reduction in the 0-5-point Cellulite Severity Scale as determined by physician assessment of Participant photographs taken before and 3 months after treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Cellulite</condition>
  <arm_group>
    <arm_group_label>RAP treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single RAP treatment applied to thigh and multi-treatment applied to the other thigh.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Soliton Rapid Acoustic Pulse (RAP)</intervention_name>
    <description>Treatment of legs and/or buttocks for the temporary improvement in the appearance of cellulite.</description>
    <arm_group_label>RAP treatment</arm_group_label>
    <other_name>RAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female ages 18-65 years

          -  Participant seeking treatment of cellulite in the upper lateral thigh areas

          -  Participant presenting with cellulite Grade I or II on BOTH thighs as graded using the
             Nurnberger-Muller scale classification (Appendix A)

          -  Participant has stable weight. Body Mass Index (B.M.I.) is ≤ 30

          -  Participant will not have any other cellulite treatments for 12 months before and
             throughout the 3-month follow-up

          -  Participant is willing to participate in study and adhere to follow-up schedule

          -  Participant is able to read and comprehend English

          -  Participant has completed Informed Consent Form

        Exclusion Criteria:

          -  Participant is pregnant or planning to become pregnant during the duration of the
             study

          -  Participant has a BMI &gt; 30

          -  Greater than 10% increase or decrease in body weight within past 6 months

          -  Cellulite treatment on the thighs or buttocks in the last 12 months (Topical or
             non-invasive procedure)

          -  Metal or plastic implants in the area of the treatment (vascular stent, or implants in
             the hips, knees, etc.)

          -  Active electronic implants such as pacemakers, defibrillators, cochlear implants,
             nerve/brain stimulators, drug pump, etc.

          -  Prior liposuction in the thighs or buttocks or any other invasive procedure to limit
             cellulite.

          -  Medical disorder that would hinder the wound healing or immune response (no blood
             disorder, diabetes, inflammatory disease, etc.)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher C Capelli, MD</last_name>
    <role>Study Director</role>
    <affiliation>Soliton</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SkinCare Physicians</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulite</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

